A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

NCT02973100 · Completed

Last updated 2026-05-28

This study tests different doses of an investigational drug called dulaglutide in adults with type 2 diabetes who are currently taking metformin alone.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 318 people

Who can join Ages 18+ · all sexes

Timeline Started 2016-12 · est. completion 2017-08

Where 66 sites · Czechia, Mexico, Poland, Puerto Rico, Romania, United States

What this study is testing ClinicalTrials.gov NCT02973100 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02973100 ↗